Hanmi Science, represented by CEO Song Young-Sook, announced on March 18th its participation in the American Association for Cancer Research (AACR 2024) in San Diego, USA, from April 5th to 10th. Hanmi Pharmaceutical, its core subsidiary, will unveil a record-breaking 10 new research projects, marking the highest number in the industry.

The research projects set to be revealed by Hanmi Pharmaceutical at AACR 2024 encompass a diverse range, including two anti-cancer drugs targeting p53-mRNA, two LAPSIL-2 analogs (development code name HM16390), two EZH1/2 dual inhibitors (HM97662), and more. These groundbreaking endeavors, presented in poster form, will be explained by researchers from Hanmi Pharmaceutical's Research and Development (R&D) Center, showcasing the innovative prowess of the Hanmi Group.

A Hanmi Science representative expressed delight at the opportunity to introduce Hanmi Pharmaceutical's innovative projects at AACR, highlighting the company's commitment to rapid commercialization and future value enhancement.

The unveiling will commence with the announcement of research results on April 7th, focusing on the 'Next-generation p53-mRNA anti-cancer drug' designed to target p53 mutations in cancer. This initiative aims to address the current lack of commercialized drugs for p53 mutations, a significant gap in cancer treatment.

On April 8th, Hanmi Pharmaceutical will present findings on HM16390, a 'Next-generation Interleukin-2 (IL-2) immunotherapy' demonstrating promising anti-tumor efficacy across various cancer types. Additionally, research results on HM97662, a 'Next-generation EZH1/2 dual inhibitor,' will be showcased, proposing a new treatment option for solid tumors with specific mutations.

Further research results, including those on a 'Selective HER2 Exon 20 Insertion Mutation Inhibitor' and 'IRE1α Inhibitor (HM100168),' will be unveiled on April 8th. On April 9th, attention will shift to BH3120, a next-generation immunotherapy spearheaded by Beijing Hanmi Pharmaceuticals, showcasing its synergistic effects in combination with PD-1 inhibitors.

Hanmi Pharmaceutical will continue its presentations with new research results on April 9th and 10th, focusing on an mRNA-based anti-cancer vaccine and a small molecule inhibitor targeting the interaction between YAP/TAZ and TEAD, respectively.

In-Young Choi, Head of R&D Center at Hanmi Pharmaceutical, emphasized the significance of this year's AACR presentation in advancing R&D innovation and solidifying Hanmi's position as a pioneer in drug development.

Juhyun Lim, President of Hanmi Group, underscored the company's unwavering commitment to drug development, reflecting the philosophy of Chairman Sung-Ki Lim.